INCIDENCE OF ADVERSE EVENTS COMPARING ABDOMINAL VS. MINIMALLY INVASIVE RADICAL HYSTERECTOMY IN PATIENTS WITH EARLY-STAGE CERVICAL CANCER: LACC TRIAL

<u>Andreas Obermair</u>, Rebecca Asher, Michael Frumovitz, Rene Pareja, Aldo Lopez, Marcelo Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Kristy P Robledo, Val Gebski, Robert L. Coleman, Gloria Salvo, Pedro T Ramirez



14 SEP 2018





17TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY

In collaboration with the Japanese Society of Gynecologic Oncology

UNITING THE GLOBE IN THE FIGHT AGAINST GYNECOLOGIC CANCER



Faculty Disclosure

No, nothing to discloseX Yes, please specify:

Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other (please specify)
SurgicalPerformance.com				x		x		
Medtronic		х	x					
OR Company	х	х						

Off-Label Product Use

Will you be presenting or referencing off-label or investigational use of a therapeutic product?

x No

Yes, please specify:



Cervical cancer

- More than 500,000 women per annum worldwide (WHO)
- Treatment of early stages is radical hysterectomy
- Increased uptake of Minimally Invasive Surgery (MIS) by surgeons
- Numerous retrospective studies or prospective case series suggested:
 - MIS associated with decreased treatment-related morbidity
 - Survival outcomes between open and MIS similar
- No prospective controlled trial available until 2007

Laparoscopic Approach to Carcinoma of the Cervix (LACC) trial






Primary objective

Disease-free survival at

4.5 years amongst patients
who underwent a total
laparoscopic or robotic radical
hysterectomy (TLRH/TRRH)
vs. a total abdominal radical
hysterectomy (TARH).



Ramirez P et al.: SGO 2018



Secondary objectives

- <u>Compare treatment-associated morbidity (up to 6 months from surgery)</u>
- Quality of Life (QoL) between arms
- Compare patterns of recurrence between arms
- Compare the cost effectiveness of TLRH/TRRH vs. TARH
- Assess pelvic floor function
- Compare overall survival between arms
- Determine the feasibility of sentinel lymph node mapping





Trial design, inclusion criteria


International, multicenter, randomized, phase III trial to test for non-inferiority of Laparoscopic/Robotic radical hysterectomy vs. open radical hysterectomy.

Inclusion criteria

- Squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of uterine cervix
- FIGO stage IA1 (with LVSI), IA2, IB1
- Type II or III radical hysterectomy (Piver-Rutledge Classification)
- Performance status of ECOG 0-1
- Age 18 years or older
- Availability of assessment of adverse events up to 3 or 6 months post-surgery



Trial schema




LACC trial enrolment was put on hold after recommendation by the DSMC in June 2017; Enrolment was stopped in September 2017. Follow up is ongoing.





LACC TRIAL (NCT00614211) **Open January 2008 – Closed to Recruitment June 2017 (631 pts)**






Country/

Surgeon proficiency

- Submission of <u>10 cases</u> of TLRH/TRRH to Trial Management Committee
 - Age EBL
 - BMI LOS
 - Stage Intraop and postop complications (<30 days)
 - OR time Transfusion rates
- Total of <u>2 un-edited videos</u> of TLRH/TRRH
- Independent Review 2 members of Trial Management Committee









IGCS 2018 KYOTO, JAPAN SEPTEMBER 14-16, 2018

Patients' characteristics

		Open	MIS
		(n = 257)	(n = 279)
Age at randomization (years)		45.8 (10.4)	46.2 (10.9)
Weight (kg)		66.3 (14.6)	68.5 (15.1)
Height (cm)		158.2 (7.5)	159.5 (6.9)
BMI (kg/m2)		26.5 (5.5)	26.9 (5.5)
Race	White/Caucasian	134 (52%)	143 (51%)
ECOG	0	236 (92%)	256 (92%)
	1	21 (8%)	23 (8%)
Stage	Stage IAI	4 (2%)	5 (2%)
	Stage IA2	18 (7%)	16 (6%)
	Stage IB1	235 (91%)	258 (92%)
Histology	Adenocarcinoma	69 (27%)	81 (29%)
	SCC	183 (71%)	193 (69%)
	Adenosquamous	5 (2%)	5 (2%)



IGCS 2018 KYOTO, JAPAN SEPTEMBER 14-16, 2018

Surgical outcomes

	Open (n = 257)	MIS (n = 279)	P-value
Length of Operation (minutes)	190 (61 – 425)	215 (75 – 441)	<.0001
Estimated blood loss (ml)	200 (0 - 2200)	100 (0 - 1500)	<.0001





Intraoperative complications

Intraoperative complications	Open (n=257)	MIS (n=279)	p-value
Any complication	26 (10%)	34 (12%)	0.450
Bladder injury	2 (1%)	7 (3%)	0.119
Blood transfusion	12 (5%)	5 (2%)	0.057
Bowel injury	1 (0%)	2 (1%)	0.611
Nerve injury*	1 (0%)	6 (2%)	0.072
Ureter injury	4 (2%)	5 (2%)	0.832
Uterus rupture	0	3 (1%)	0.095
Vaginal laceration	0	2 (1%)	0.173
Vascular injury	3 (1%)	4 (1%)	0.786
Other**	3 (1%)	5 (2%)	0.526

*Genitofemoral N (3); Obturator N (2); Femoral Cutaneous Lateral N (1); Femoral N (1)

IGCS 2018 **Bleeding; uterine perforation; PID

KYOTO, JAPAN

SEPTEMBER 14-16, 2018



Postoperative complications (CTC grade 2+)

	Open	MIS	
	(n = 257)	(n = 279)	p-value
Wound complications	16 (6.2%)	4 (1.4%)	0.003
Surgical site infection	4 (1.6%)	5 (1.8%)	0.832
Incisional or port site hernia	1 (0.4%)	0 (0.0%)	0.297
Febrile morbidity	2 (0.8%)	6 (2.2%)	0.190
Vaginal vault complications*	2 (0.8%)	11 (3.9%)	0.017
Acute renal injury	1 (0.4%)	1 (0.4%)	0.953
Genitourinary fistula or stricture	7 (2.7)	10 (3.6%)	0.570
GI fistula	0 (0.0%)	1 (0.4%)	0.336
GI obstruction	1 (0.4%)	3 (1.1%)	0.356
lleus	2 (0.8%)	0 (0.0%)	0.139
Neuropathy	2 (0.8%)	7 (2.5%)	0.119
DVT/PE	0 (0.0%)	1 (0.4%)	0.336
Lymphocele formation	3 (1.2%)	0 (0.0%)	0.070
Pain	24 (9.3%)	19 (6.8%)	0.281
Nausea	9 (3.5%)	8 (2.9%)	0.675
Lymphedema	2 (0.8%)	1 (0.4%)	0.515
Anaemia	16 (6.2%)	16 (5.7%)	0.810
Anxiety	3 (1.2%)	2 (0.7%)	0.587
Any other AE	86 (33.5%)	95 (34.1%)	0.885

ocgc research

*Vault infection, bleeding/spotting and dehiscence

KYOTO, JAPAN

SEPTEMBER 14-16, 2018

Postoperative complications (cont'd) (CTC grade 2+)

	Open	MIS	
	(n = 257)	(n = 279)	p-value
Any pulmonary complications	3 (1.2%)	5 (1.8%)	0.551
Any cardiac complications	10 (3.9%)	2 (0.7%)	0.013
Any urinary complications*	46 (17.9%)	63 (22.6%)	0.178
Any sepsis	2 (0.8%)	2 (0.7%)	0.934
Any GI complications	36 (14.0%)	44 (15.8%)	0.567
Any Serious Adverse Event**	28 (10.9%)	39 (14.0%)	0.280

*Including bladder dysfunction

**Death; Immediately life threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity





Summary of complications

	Open	MIS	
	(n = 257)	(n = 279)	P value
Any complication	118 (46%)	145 (52%)	0.161
Intra-operative complications	26 (10%)	34 (12%)	0.447
Early post-operative morbidity	84 (33%)	99 (35%)	0.494
(CTC grade 2+; <6 weeks)			
Delayed morbidity	44 (17%)	55 (20%)	0.439
(CTC grade 2+; 3 to 6 months)			





Complications by groups

	Open (n = 257)	Lap (n = 238)	Robotic (n=41)
Any complication (any grade)	118 (46%)	124 (52%)	21 (51%)
Intra-operative complications	26 (10%)	30 (13%)	4 (10%)
Early post-operative morbidity (CTC grade 2+; <6 weeks)	84 (33%)	84 (35%)	15 (37%)
Delayed morbidity (CTC grade 2+; 3 to 6 months)	44 (17%)	48 (20%)	7 (17%)





Conclusions

- Anticipated benefits of laparoscopic/robotic radical hysterectomy over open radical hysterectomy were not demonstrated
- Length of surgery greater in laparoscopic/robotic group
- Estimated blood loss less in laparoscopic/robotic group
- Intraoperative, postoperative and serious adverse events are similar in both groups.





Discussion

STRENGTHS

- Prospective capture of AEs
- Robust trial design
- Appropriately powered
- Multicentre & international collaboration
- Surgeon proficiency requirements

LIMITATIONS

- Allowed laparoscopic and robotic surgery
- Documentation of AEs higher than clinically relevant
 - Numbness, vault spotting, vaginal laceration, bladder serosal tear





Acknowledgments

- Patients
- Surgeons
- Investigators
- Statistics: Val Gebski, Kristy Robledo, Rebecca Asher
- Recurrence adjudication committee: David Cibula, Gregg Nelson, Mario Leitao
- Data Management and Safety Committee: Robert Edwards (Chair); Ralph Freedman; Neely Atkinson; Jeffrey Fowler; Paola Gehrig; Wendel Nauman; Alexander Olawaiye; Jennifer Davis.



